The product will be available under Obeda brand, the same name under which the Hyderabad-based generic drugmaker had rolled out the generic version of the type 2 diabetes drug in injection form on March 21.
| Photo Credit: The Hindu
Dr. Reddy’s Laboratories has launched in India oral semaglutide biosimilar in tablet form.The product will be available under Obeda brand, the same name under which the Hyderabad-based generic drugmaker had rolled out the generic version of the type 2 diabetes drug in injection form on March 21.The launch in tablet form comes days after it introduced its generic Semaglutide injection in Canada, “further establishing the position as a full‑stack player in GLP‑1 therapies,” Dr. Reddy’s said in a release on Wednesday (May 20, 2026). A prescription-based drug, the tablets are available in 3 mg, 7 mg and 14 mg strengths. It is priced at ₹99, ₹135, and ₹225 per tablet for the 3 mg, 7 mg, and 14 mg doses, respectively, the company said.“With this launch, we are broadening our GLP‑1 portfolio. As the product is developed and formulated in-house, we are committed to reliable supply and consistent quality for patients in India,” CEO-Global Generics M.V. Ramana said.Semaglutide is the active ingredient in Danish major Novo Nordisk’s blockbuster diabetes and weight loss drugs, Wegovy and Ozempic. Soon after the patent on Semaglutide expired, a clutch of drugmakers in India, including Dr. Reddy’s rolled out their generic versions of the product, triggering a price war and eyeing a pie of the market.Dr. Reddy’s said Obeda (semaglutide tablets) is formulated using recombinant DNA (rDNA) origin of semaglutide active pharmaceutical ingredient. It had obtained approval for its oral semaglutide biosimilar from the CDSCO following a review of a Phase III clinical study enrolling 288 participants with type 2 diabetes mellitus conducted in India, which demonstrated non-inferior efficacy and a safety profile comparable to the innovator oral drug. Published - May 20, 2026 10:10 pm IST
